Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Multiple sclerosis (relapsing) - teriflunomide: evaluation report

01. NICE’s response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD – Genzyme

03. Manufacturer’s additional information (Genzyme)

04. Manufacturer’s appendices (Genzyme)

05. Manufacturer’s meta-regression analyses report (Genzyme)

06. Consultee comments on the ACD – Multiple Sclerosis Society

07. Consultee comments on the ACD – Multiple Sclerosis Trust

08. Consultee comments on the ACD – Association of British Neurologists

09. Consultee comments on the ACD - Royal College of Nursing

10. Consultee comments on the ACD - United Kingdom Clinical Pharmacy Association

11  Commentator comments on the ACD – Biogen Idec

12. Commentator comments on the ACD – Merck Serono

13. Commentator comments on the ACD – Novartis

14. Clinical expert comments on the ACD – RASHID

15. Patient expert comments on the ACD – RIJKE

16. ERG critique of additional information from the manufacturer

* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *